



GM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells

OPEN ACCESS

Edited by:

Ivan Zanoni,
Harvard Medical School, USA

Reviewed by:

Silvano Sozzani,
University of Brescia, Italy
Laura Santambrogio,
Albert Einstein College of Medicine,
USA
F. Ronchese,
Malaghan Institute of Medical
Research, New Zealand

*Correspondence:

Francesca Di Rosa
francesca.dirosa@uniroma1.it

[†]These authors have contributed
equally to this work.

*Present address:

Sara Vitale,
Istituto Superiore di Sanità, Rome,
Italy;
Daniele Runci,
Department of Pathology and
Immunology, Washington University
School of Medicine, St. Louis,
MO, USA

Specialty section:

This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology

Received: 05 August 2016

Accepted: 30 January 2017

Published: 16 February 2017

Citation:

Barroeta Seijas AB, Simonetti S,
Vitale S, Runci D, Quinci AC,
Soriani A, Criscuoli M, Filippi I,
Naldini A, Sacchetti FM, Tarantino U,
Oliva F, Piccirilli E, Santoni A and
Di Rosa F (2017) GM-CSF Inhibits
c-Kit and SCF Expression by Bone
Marrow-Derived Dendritic Cells.
Front. Immunol. 8:147.
doi: 10.3389/fimmu.2017.00147

Amarelys Belen Barroeta Seijas^{1,2†}, Sonia Simonetti^{2†}, Sara Vitale^{1†}, Daniele Runci^{3†}, Angela Caterina Quinci², Alessandra Soriani², Mattia Criscuoli⁴, Irene Filippi⁴, Antonella Naldini⁴, Federico Maria Sacchetti⁵, Umberto Tarantino⁶, Francesco Oliva⁶, Eleonora Piccirilli⁶, Angela Santoni^{2,3} and Francesca Di Rosa^{1*}

¹Institute of Molecular Biology and Pathology, National Research Council (CNR), c/o Department of Molecular Medicine, University of Rome "Sapienza", Rome, Italy, ²Department of Molecular Medicine, University of Rome "Sapienza", Rome, Italy, ³Istituto Pasteur Italia – Fondazione Cenci Bolognetti, Rome, Italy, ⁴Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy, ⁵Centro Traumatologico Ortopedico Andrea Alesini Hospital, Rome, Italy, ⁶Department of Orthopaedics and Traumatology, University of Rome "Tor Vergata", Rome, Italy

Stem cell factor (SCF), the ligand of c-kit, is a key cytokine for hematopoiesis. Hematopoietic precursors express c-kit, whereas differentiated cells of hematopoietic lineage are negative for this receptor, with the exception of NK cells, mast cells, and a few others. While it has long been recognized that dendritic cells (DCs) can express c-kit, several questions remain concerning the SCF/c-kit axis in DCs. This is particularly relevant for DCs found in those organs wherein SCF is highly expressed, including the bone marrow (BM). We characterized c-kit expression by conventional DCs (cDCs) from BM and demonstrated a higher proportion of c-kit⁺ cells among type 1 cDC subsets (cDC1s) than type 2 cDC subsets (cDC2s) in both humans and mice, whereas similar levels of c-kit expression were observed in cDC1s and cDC2s from mouse spleen. To further study c-kit regulation, DCs were generated with granulocyte-macrophage colony-stimulating factor (GM-CSF) from mouse BM, a widely used protocol. CD11c⁺ cells were purified from pooled non-adherent and slightly adherent cells collected after 7 days of culture, thus obtaining highly purified BM-derived DCs (BMdDCs). BMdDCs contained a small fraction of c-kit⁺ cells, and by replating them for 2 days with GM-CSF, we obtained a homogeneous population of c-kit⁺ CD40^{hi} MHCII^{hi} cells. Not only did BMdDCs express c-kit but they also produced SCF, and both were strikingly upregulated if GM-CSF was omitted after replating. Furthermore, a small but significant reduction in BMdDC survival was observed upon SCF silencing. Incubation of BMdDCs with SCF did not modulate antigen presentation ability of these cells, nor it did regulate their membrane expression of the chemokine receptor CXCR4. We conclude that the SCF/c-kit-mediated prosurvival circuit may have been overlooked because of the prominent use of GM-CSF in DC cultures *in vitro*, including those human DC cultures destined for the clinics. We speculate that DCs more prominently rely on SCF *in vivo* in some microenvironments, with potential implications for graft-versus-host disease and antitumor immunity.

Keywords: bone marrow-derived dendritic cells, conventional dendritic cell subsets, bone marrow, dendritic cell survival, dendritic cell homeostasis, GM-CSF, stem cell factor

INTRODUCTION

Dendritic cells (DCs) are cells of hematopoietic origin that develop in the bone marrow (BM) and play a key role in immunity and tolerance. Resting DCs are scattered as sentinels in tissues throughout the body, contributing to maintain tolerance in healthy conditions (1, 2). Upon pathogen entry, tissue DCs become activated, uptake and process antigens, and acquire an increased capacity to migrate to draining lymph nodes (LNs). Changes in migratory behavior of activated DCs are reflected by modulation of chemokine receptors, for instance, upregulation of CCR7, the receptor for CCL19/21, and of CXCR4, the receptor for CXCL12 (3–6). Fully activated or mature DCs act as professional antigen-presenting cells (APCs), with the unique ability to prime naïve CD4 and CD8 T cells (2, 7). Furthermore, DCs orchestrate immune response by producing a wide array of membrane molecules, cytokines, and chemokines (8). After activation, DCs are destined to die by apoptosis or necroptosis, depending on the maturing stimuli (9, 10). DC survival is also regulated by several inflammatory cytokines, including type I interferon (IFN) and IL-15 (11, 12).

Distinct DC subsets have been identified (2, 13). Classical or conventional DCs (cDCs) are specialized in antigen processing and presentation, whereas plasmacytoid DCs (pDCs) produce high levels of type I IFN in response to viral infection (2). In mice, cDCs express high levels of CD11c integrin, while pDCs have an intermediate expression of this marker (14). At least two cDC subsets have been identified: the most abundant type 2 cDC subset (cDC2) expresses CD11b in mice and CD1c in humans; the type 1 cDC subset (cDC1) expresses CD8 α and/or CD103 in mice and CD141 in humans (14). Under pathological conditions, novel DC subsets could appear, for example, monocyte-derived inflammatory DC (15). Different sets of chemokine receptors are expressed by DC subsets, for example, CX3CR1, the receptor for fractalkine, is expressed by pDCs, human blood cDC2, and kidney DCs (16–18).

Peripheral DCs have a finite life span (19). DCs mostly derive from common myeloid progenitors (CMPs) in the BM, with some contribution by common lymphoid precursors (2). Both FMS-like tyrosine kinase 3 ligand (Flt3-L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) regulate DC development and maintenance of normal differentiated DC numbers (20–22). In the absence of GM-CSF, cDC numbers in spleen and LN were decreased about 2- and 4-fold, respectively; cDC reduction was more prominent in Flt3-L ko mice, and pDCs were also greatly impaired in these mice (21). Data in Flt3 ko and Flt3/GM-CSF receptor double ko mice supported a specific role for Flt3 signaling in cDC maintenance (23). Notably, some residual cDCs were found in the spleen and BM of Flt3-L ko mice, and they were still present in Flt3-L/GM-CSF double ko mice (21). Altogether, these results suggest that some unknown mechanisms might contribute to differentiated DC survival in lymphoid organs (21).

Dendritic cells can express c-kit, the receptor for stem cell factor (SCF) (13, 24). In a mouse model of allergic asthma, it was found that c-kit was expressed by DCs from lung of mice immunized intranasally with OVA/cholera toxin or OVA/CpG, but not

by lung DCs from untreated mice (25). Activation of SCF/c-kit axis in DC promoted Th2 and Th17 but not Th1 response (25–27). Under physiological conditions, lymphoid-tissue cDCs but not pDCs express c-kit (13, 14, 28). Despite increasing knowledge of location-specific DC characteristics, several questions regarding c-kit expression by DCs remain, for instance whether DCs from different lymphoid organs display differences in c-kit expression, and whether SCF binding to c-kit plays a role in DC homeostasis particularly in those organs wherein SCF is highly expressed, such as the BM (29).

In the BM, fibroblasts, endothelial cells, and other cell types produce SCF, an essential cytokine for hematopoiesis, that is also required for germ cell and melanocyte development (29–32). Soluble and membrane isoforms of SCF are generated as a result of alternative splicing and proteolytic cleavage (33). Binding of SCF to its membrane receptor c-kit (also called CD117) activates intracellular signaling molecules including PI-3 kinase, PLC γ , src-family kinases, and regulating cell survival, proliferation, adhesion (32–34).

In this paper, we evaluated c-kit expression by DC subsets in mouse and human BM and studied SCF/c-kit axis in DCs generated *in vitro* from mouse BM.

MATERIALS AND METHODS

Cytokines and Culture Media

Recombinant mouse SCF and Flt3-L were purchased from Immunotools (Friesoythe, Germany), recombinant mouse GM-CSF from Peprotech (Rocky Hill, NJ, USA). Opti-MEM Medium (Thermo Fisher Scientific, Waltham, MA, USA) was supplemented with glutamine, penicillin/streptomycin, 50 μ M β -mercaptoethanol (Complete Opti-MEM medium). Complete Opti-MEM medium was not supplemented with any serum, except in the cultures with OT-1 and OT-2 cells, as indicated. RPMI Medium 1640 (Sigma-Aldrich, Milan, Italy) was supplemented as above, plus 10% heat-inactivated fetal calf serum (FCS) (complete RPMI medium). Opti-MEM is an optimized version of MEM containing insulin and transferrin, but does not contain GM-CSF, Flt3-L, SCF, or other cytokines (personal communication from Thermo Fisher Scientific Technical Support).

Mouse Sample Collection and Preparation

Female C57BL/6J (B6) and OT-2 TCR transgenic mice were purchased from Charles River and housed at the animal facility of Istituto Superiore di Sanità of Rome (ISS), according to institutional guidelines (DL116/92 and 26/2014). Female OT-1 TCR transgenic mice were kindly provided by Dr. M. R. Castrucci (ISS). The OT-1 transgenic TCR recognizes the Kb-restricted OVA 257–264 peptide (35), while the OT-2 transgenic TCR recognizes the I-Ab-restricted OVA 323–339 peptide (36). CX3cr1^{gfp/+} and CX3cr1^{gfp/gfp} B6 mice were purchased from JAX Mice and Services (Bar Harbor, ME, USA) (37). Mice were sacrificed at 5–16 weeks of age and spleen, peripheral, and mesenteric LNs and BM obtained as we previously described (38, 39). In some experiments, CD11c⁺ cells were enriched from either spleen or BM with anti-CD11c magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).

BM-Derived DCs (BMdDCs)

We generated DCs from BM cells as previously described (40, 41), with few modifications. Briefly, $10\text{--}15 \times 10^6$ BM cells were cultured in complete RPMI medium with 20 ng/ml of GM-CSF in Petri dishes (BD Falcon, BD Biosciences, San Jose, CA, USA). After 3 days, fresh medium with GM-CSF was added. At day 7, we collected non-adherent and slightly adherent cells after detachment with PBS 3 mM EDTA. CD11c⁺ cells were purified with anti-CD11c magnetic microbeads (Miltenyi Biotec), thus obtaining BMdDCs. In some experiments, DCs were generated by culturing BM cells with Flt3-L at 100 ng/ml for 8 days, as previously described (42).

Antigen Presentation Assay

OT-1 and OT-2 mice were sacrificed and single cell suspensions were obtained from spleen and LNs. OT-1 CD8⁺ and OT-2 CD4⁺ cells ($\geq 87\%$ pure) were obtained after incubation with anti-CD8 β .2 fluorescein isothiocyanate (FITC) monoclonal antibody (mAb) (BD) and CD4 FITC mAb (BD), respectively, followed by positive selection with anti-FITC magnetic microbeads (Miltenyi Biotec). Cells were labeled for 8 min at room temperature with 2.5 μ M carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR, USA). For antigen presentation assays, BMdDCs were kept for 2 days in complete Opti-MEM medium with GM-CSF at 20 ng/ml, then incubated for 5 h with Ovalbumin (OVA, Hyglos GmbH, Resenbug, Germany) at 0.2 mg/ml, in the presence or not of SCF at 100 ng/ml. After extensive washings, BMdDCs ($200\text{--}250 \times 10^3$ cells/well) were cocultured in flat-bottom 96-well plates in complete Opti-MEM medium with 5% FCS with either purified CFSE-labeled OT-1 CD8⁺ ($700\text{--}750 \times 10^3$ cells/well) or purified CFSE-labeled OT-2 CD4⁺ (200×10^3 cells/well) cells for 3 days. CFSE dilution by TCR⁺ CD8⁺ and TCR⁺ CD4⁺ cells was evaluated by flow cytometry (43–45).

Membrane Staining and Flow Cytometry

Cell membrane staining was performed with fluorochrome-conjugated mAbs, after blocking with anti-Fc γ R (clone 2.4G2) mAb. The following mAbs were used (clone indicated in parentheses): anti-CD11c (HL3), anti-I-Ab or MHCII (M5/114.15.2) anti-CD40 (HM40-3), anti-CD11b (M1/70), anti-CD8 α (53-6.7), anti-CD3 (145-2C11), anti-NK1.1 (PK136), anti-c-kit (2B8), anti-TCR β (H57-597); anti-CD4 (RM4-4); anti-CD8 β .2 (53-5.8); anti-CXCR4 (2B11) [from BD Biosciences; Biolegend, San Diego, CA, USA; Miltenyi Biotec; eBioscience; conjugated with FITC, phycoerythrin (PE), peridinin chlorophyll protein (PerCP)-Cy5.5, PE-Cy7, Alexa 647, APC, APC-Vio770; APC-H7]. Dead cells were excluded with Propidium Iodide (PI, Sigma-Aldrich). Samples were analyzed by FACSCanto I and II (BD Biosciences). Data were analyzed using FlowJo software, v.9.7.6 (FlowJo, Ashland, OR, USA).

Real-time PCR

Total RNA was extracted by TriReagent (Sigma-Aldrich). One microgram of total RNA was used for cDNA first-strand synthesis according to the manufacturer's protocol for Moloney

MLV reverse transcriptase (Promega, Madison, WI, USA). Real-time PCR was performed using the ABI Prism 7900 sequence detection system (Applied Biosystems, Foster City, CA, USA). cDNAs were amplified in triplicate with primers for c-kit (Mm00445212_m1), SCF (Mm00442972_m1), and hprt-1 (Mm00446968_m1) (Applied Biosystems, Thermo Fisher Scientific), all conjugated with fluorochrome FAM. Relative expression of each gene versus hprt-1 was calculated according to the $2^{-\Delta\Delta Ct}$ method.

Western Blot

Immunoblotting was performed as we previously described, after cell lysis with 1% Triton X-100, 0.1% SDS Tris buffer containing protease inhibitor cocktail (Sigma-Aldrich) and the phosphatase inhibitors NaF, Na₃VO₄, phenylmethylsulfonyl fluoride (46). Equal amounts of proteins were separated by 10% SDS-PAGE, transferred onto PVDF membrane by Trans-Blot TurboTM Transfer System (Bio-Rad Laboratories), and probed with anti-phospho-AKT (Ser 473), anti-AKT and anti- β -actin antibodies (Cell Signaling Technology, Danvers, MA, USA). Chemiluminescence detection was performed by a CCD camera gel documentation system (ChemiDocXRS, Bio-Rad Laboratories, Hercules, CA, USA).

ELISA

BM-derived DCs were lysed as above without the phosphatase inhibitors. BMdDC culture supernatants (100 μ l/well) and BMdDC lysates (25 μ g of cell lysate/well) were tested by mouse SCF ELISA kit (Boster Immunoleader, Pleasanton, CA, USA).

SCF Silencing

Stem cell factor silencing was performed by transfecting BMdDCs with Lipofectamine[®] RNAiMax reagent (Invitrogen, Thermo Fisher Scientific) using the following siRNAs: SCF-siRNA (sc-39735, consisting of a pool of three target-specific 19–25 nt siRNA), scrambled control-A siRNA (sc-37007), fluorescein conjugated control-A siRNA (sc-36869), all from Santa Cruz (Dallas, TX, USA).

Cell Viability Assay by Flow Cytometry

Stem cell factor- or control-silenced BMdDCs were cultured for 2 days in 96-well plates at 2×10^5 /well in complete Opti-MEM medium with or w/o GM-CSF at 20 ng/ml. Cells were then collected, stained with Annexin V FITC and PI, and analyzed by flow cytometry. In experiments with blocking anti-c-kit mAb, BMdDCs were cultured as above in the presence of 10 μ g/ml of either anti-c-kit (ACK2) or isotype control (RTK4530) mAb (both Low Endotoxin Azide Free, Biolegend). After 2 days, cells were collected and analyzed by Annexin V FITC/PI as above.

Cell Number Determination

BM-derived DC numbers were determined by the CyQUANT Cell Proliferation Assay kit from Invitrogen according to manufacturer's instructions. Optical density was determined using a VICTOR X Multilabel Plate Reader.

Human BM Samples Collection and Flow Cytometric Analysis

Pieces of spongy bone, which would otherwise have been discarded, were obtained from systemically healthy patients undergoing hip replacement at either Centro Traumatologico Ortopedico Andrea Alesini Hospital or Policlinico Tor Vergata, Rome, after approval by Institutional Ethics Committee, and informed consent from patients in accordance with the Declaration of Helsinki (study no. 129.14, prot 76699 and study no. 156.15, prot. 0030053/2015). BM mononuclear cells were isolated by Lympholyte-H (Cedarlane, NC, USA) density-gradient centrifugation. Flow cytometry was performed as above, using FcR Blocking Reagent and Dead Cell Discrimination Kit (Mitenyi Biotec) before addition of the following fluorochrome-conjugated mAbs: CD1c or BDCA-1 (AD5-8E7), CD141 or BDCA-3 (AD5-14H12), CD45 (2D1) CD14 (TÜK4), CD19 (LT19), c-kit (104D2) [from BD Biosciences; Miltenyi Biotec; Exbio, Prague, Czech Republic; conjugated with phycoerythrin (PE), PerCP-Vio700, PE-Cy7, APC, APC-H7]. Cells were fixed with PBS formaldehyde 1.2% before flow cytometric analysis.

Statistics

We performed a two-tailed paired Student's *t*-test using Prism v.6.0f, GraphPad Software (La Jolla, CA, USA). Differences were considered significant when **P* ≤ 0.05, ***P* ≤ 0.01, ****P* ≤ 0.001.

RESULTS

c-Kit Is Expressed by a Fraction of DCs in the BM of WT Mice

We analyzed membrane c-kit expression by BM and spleen DCs freshly obtained from untreated C57BL/6J (B6) mice, gating on CD11c^{hi} MHC-II⁺ DC as previously described (47). Typical flow cytometry profiles are shown in **Figure 1A** (see Figure S1A in Supplementary Material for our gating strategy, based on forward and side scatter plots and exclusion of CD3⁺, NK1.1⁺, and dead cells). While the great majority of spleen DCs expressed membrane c-kit, only a small percentage of BM DCs was c-kit⁺ (**Figures 1A,B**). Results were similar after about 100-fold enrichment of CD11c⁺ cells by immunomagnetic selection (Figures S2A,B in Supplementary Material). c-kit⁺ DCs were characterized by intermediate levels of membrane c-kit, that is <10⁴ fluorescence intensity, whereas other cells in spleen and BM were c-kit^{hi} (**Figure 1C**). We observed that MHC-II median fluorescence intensity (MFI) was higher in BM DCs than in spleen DCs, in agreement with previous results (47). Furthermore, MHC-II MFI was higher in c-kit⁺ BM DCs than in c-kit⁺ spleen DCs (**Figure 1D**).

c-Kit and High CX3CR1 Expression by BM DCs Are Inversely Correlated in a CX3CR1-GFP Reporter Mouse

It was previously shown that most BM DCs are characterized by high CX3CR1 expression, using a mouse model in which green fluorescence protein (GFP) replaces CX3CR1 by gene

targeting (47). We analyzed BM DCs from CX3cr1^{gfp/+} mice by flow cytometry to investigate c-kit expression in respect to GFP intensity. We found that c-kit was expressed by the few intermediate green but not by the large population of bright green BM DCs from CX3cr1^{gfp/+} mice (**Figure 1E**), whereas in the spleen most CX3cr1^{gfp/+} spleen DCs were c-kit⁺ and had intermediate green fluorescence intensity (**Figure 1E**). Furthermore, CX3CR1-deficient CX3cr1^{gfp/gfp} BM DCs contained a significantly higher percentage of c-kit⁺ cells than WT BM DCs, while the percentage of c-kit⁺ cells within spleen DCs was similar in WT, CX3cr1^{gfp/+}, and CX3cr1^{gfp/gfp} mice (**Figure 1F**; Figures S2C,D in Supplementary Material). These results suggest that c-kit expression and high levels of CX3CR1 are inversely correlated in BM DCs and that the presence of c-kit⁺ DCs in the BM does not depend on CX3CR1 expression.


c-Kit Is Expressed by All cDC1s and by a Fraction of cDC2s in the BM of WT Mice

We then performed flow cytometric analysis of cDC subsets from spleen and BM of WT mice, by gating on either cDC1s or cDC2s, based on CD8α and CD11b expression (14, 48). We found that virtually all cDC1s and a small proportion of cDC2s expressed c-kit in the BM, whereas both cDC subsets were c-kit⁺ in the spleen (**Figures 2A,B**). The difference in c-kit percentages between BM cDC1s and cDC2s was statistically significant (**Figure 2C**). In the BM, c-kit⁺ DCs expressed intermediate levels of CD11b, while c-kit⁻ DCs were CD11b^{hi} (**Figure 2A**, right top panel).

An *In Vitro* Culture System to Analyze c-Kit Expression by Mouse BMdDCs

We compared c-kit membrane expression by DCs obtained from mouse BM cells differentiated *in vitro* with either GM-CSF or Flt3-L (40–42). Both protocols resulted in a small percentage of c-kit⁺ within CD11c⁺ cells (Figures S3B,D in Supplementary Material; gating strategy in Figures S3A,C in Supplementary Material). However, DCs generated with GM-CSF were characterized by increased cell yield and higher cell viability (Figures S3A–D in Supplementary Material and data not shown). Thus, we decided to use GM-CSF for further experiments and to magnetically select CD11c⁺ cells from the fraction including non-adherent and slightly adherent cells at day 7 to obtain highly purified DCs (called “BM-derived DCs or BMdDCs,” see Figures S3E,F in Supplementary Material). On average, 15% of the BMdDCs were MHC-II^{hi} CD40^{hi} CD11b^{int} and 76% MHC-II^{int} CD40^{int} CD11b^{hi} cells (see example in **Figure 3A**, top panel). c-kit was expressed only by the MHC-II^{hi} CD40^{hi} cells, suggesting that it is a marker of the more mature cells (**Figure 3B**, top panels). The c-kit⁺ BMdDCs were all CD11b^{int}, whereas the remaining c-kit⁻ cells were CD11b^{hi} (**Figure 3C**, top panel).

To increase the proportion of c-kit⁺ cells, we replated BMdDCs in different culture conditions, all with GM-CSF at 20 ng/ml, and then analyzed their membrane phenotype (Figures S4A,B in Supplementary Material and data not shown). After 2 days of culture in complete Opti-MEM medium, the majority of




BMDcDs were MHC-II^{hi} CD40^{hi} CD11b^{int}, and expressed c-kit⁺ (Figures 3A–C, bottom panels). Membrane c-kit fluorescence intensity significantly increased within the MHC-II^{hi} CD40^{hi} cells, while the MHC-II^{int} CD40^{int} cells remained negative for this marker (Figures 3B,D). c-kit mRNA expression increased significantly, indicating that membrane c-kit up-regulation depended on increased transcription (Figure 3E).

We usually collected non-adherent and slightly adherent BMDcDs when we harvested cells 2 days after replating. In some experiments, we separately analyzed adherent cells and found that they comprised a higher proportion of MHC-II^{int} CD40^{int} cells compared to the floating fraction of BMDcDs. Nevertheless, a high percentage (>70%) of adherent cells was


still MHC-II^{hi} CD40^{hi}, confirming that MHC-II^{hi} CD40^{hi} cells represented the large majority of BMDcDs after 2 days of culture in our conditions (Figure S4C in Supplementary Material). Notably, as for the non-adherent fraction, the MHC-II^{hi} CD40^{hi} cells were the only c-kit⁺ cells in the adherent fraction (Figure S4D in Supplementary Material).

SCF/c-Kit Axis Is Functional in BMDcDs and Does Not Influence OVA Presentation by BMDcDs

To determine whether c-kit could function as a signal transducing receptor, c-kit⁺ BMDcDs were stimulated with SCF and



analyzed for phosphorylated Akt, a serine-threonine kinase located downstream of PI3-kinase with an essential role in cellular survival and proliferation (34). After incubation with SCF, phospho-Akt levels increased rapidly, while total Akt remained unchanged (**Figures 3F,G**).



To evaluate the effect of SCF on the capacity of *c-kit*⁺ BMdDCs to present the model antigen OVA, we assessed the proliferation of OVA-specific T cells from TCR transgenic mice OT-1 and OT-2, by CFSE dilution. We observed that both OT-1 (Figures 4A,B) and OT-2 (Figures 4C,D) cells proliferated in response to BMdDCs preincubated with OVA, showing the functionality of both MHC-I and MHC-II presentation pathways. The presence of SCF during preincubation of BMdDCs with OVA did not influence the proliferation of neither OT-1 (Figures 4A,B) nor OT-2 (Figures 4C,D) cells.

GM-CSF Inhibits *c-Kit* Membrane Expression by BMdDCs

Since GM-CSF can inhibit *c-kit* expression by mast cells (49, 50), we next evaluated the effects of GM-CSF in our BMdDC cultures, by comparing *c-kit* membrane expression by BMdDCs cultured in complete Opti-MEM medium either with or without GM-CSF at 20 ng/ml. Furthermore, considering the possible intercellular

competition for GM-CSF, we cultured BMdDCs at two different cell densities, i.e., about 6.3×10^5 and 1×10^5 cells/cm², corresponding to 1.2×10^6 and 0.2×10^6 cells/well in 24-well plate, respectively. We observed that *c-kit* membrane expression by MHC-II^{hi} CD40^{hi} cells was higher when BMdDCs were cultured at higher cell density, and in particular, MHC-II^{hi} CD40^{hi} cells had extremely high *c-kit* fluorescence intensity when cultured without GM-CSF if compared to BMdDCs cultured in the presence of GM-CSF (Figures 5A–C).

Stem cell factor can be produced by a variety of cell types, including DCs (25, 29, 30). We found that BMdDCs produced cell-associated SCF and its levels remained stable after 2 days of culture in complete Opti-MEM medium with GM-CSF. When BMdDCs were cultured in the absence of GM-CSF, cell-associated SCF significantly increased (Figure 5D). SCF concentration in supernatants was 50.33 ± 1.05 pg/ml after 2 days of culture in the presence of GM-CSF and did not increase in the absence of GM-CSF (data not shown). Notably,





FIGURE 4 | Antigen presentation by BM-derived DCs (BMdDCs) is not modulated by stem cell factor (SCF). Day 2 BMdDCs, obtained as in Figure 3, were incubated for 5 h with OVA at 0.2 mg/ml, in the presence or not of SCF at 100 ng/ml. After extensive washings, BMdDCs were cocultured with either CFSE-labeled purified OT-1 or CFSE-labeled purified OT-2 cells for 3 days. CFSE dilution was evaluated by flow cytometry. (A,C) Typical CFSE profiles, after gating on TCR⁺ CD8⁺ for OT-1 (A) and TCR⁺ CD4⁺ for OT-2 T cells (C). Numbers represent percentages of cells in the indicated regions. (B,D) Summary of OT-1 (B) and OT-2 (D) proliferation results from individual samples and average values (bar). In (A,C) representative data of $N = 3$ experiments, in (B,D) $N = 3$ experiments (* $P \leq 0.05$; ** $P \leq 0.01$).


SCF expression increased at the mRNA level when BMdDCs were cultured for 2 days without GM-CSF (Figure 5E). Thus, BMdDCs can produce SCF, but the presence of GM-CSF interferes with this process.

SCF Does Not Modulate CXCR4 Membrane Expression by BMdDCs

CXCR4 plays a key role in leukocyte retention in the BM, by interacting with CXCL12 (51). Moreover, DC maturation

results in upregulation of CXCR4 (3, 5). We compared CXCR4 membrane expression by BMdDCs cultured in complete Opti-MEM medium either with or without GM-CSF at 20 ng/ml and evaluated whether an overnight addition of SCF to these cultures modulated CXCR4. MHC-II^{hi} CD40^{hi} cells had always a higher CXCR4 MFI than MHC-II^{int} CD40^{int} cells (Figures 6A,B). CXCR4 expression by MHC-II^{hi} CD40^{hi} cells increased in the absence of GM-CSF, and the addition of SCF to the culture did not influence the expression of CXCR4 (Figures 6B,C).





SCF Is an Autocrine Survival Factor for BMdDCs

To evaluate whether BMdDC survival could be modulated by SCF autocrine production, SCF was silenced by transfection with SCF-siRNA and cell survival analyzed after 2 days of culture either with or without GM-CSF. In our conditions, transfection efficiency was about 40%, as evaluated in control cells transfected in parallel with fluorescein-conjugated RNA, and SCF protein concentration in lysates from SCF-siRNA-silenced cells was about 70% that in lysates from scrambled siRNA-silenced control cells (e.g., 489 pg/ml in SCF-silenced cells and 671 pg/ml in control cells, in cultures with GM-CSF; 589 pg/ml in SCF-silenced cells and 714 pg/ml in control cells, without GM-CSF). Although SCF expression was only partially reduced, we observed a statistically significant decrease in cell survival in the cultures with GM-CSF, based on Annexin V/PI staining (**Figures 7A,B**). Absolute cell numbers were significantly

decreased upon SCF silencing in both BMdDC cultures, with and without GM-CSF (**Figure 7C**). In a different set of experiments, we cultured BMdDCs for 2 days in the presence of 10 μ g/ml of either the anti-c-kit blocking mAb ACK2 or its corresponding control mAb and observed a modest but statistically significant decrease in cell survival, based on Annexin V/PI staining (Figure S5 in Supplementary Material). Results were similar in BMdDC culture with and without GM-CSF (Figure S5 in Supplementary Material). Altogether, these findings indicate that DCs promote their own survival both by the autocrine production of SCF and by expressing the receptor c-kit.

c-Kit Is Preferentially Expressed by cDC1s in Human BM

We also analyzed cDC from human BM samples, by using high levels of CD141 and expression of CD1c as markers for cDC1s and cDC2s, respectively (14, 52). Typical examples of human BM





FIGURE 7 | Negative effect of stem cell factor (SCF) silencing on BM-derived DC (BMdDC) survival. BMdDCs were transfected with either SCF-siRNA or control-scrambled (scr1) siRNA, or else left untreated. Cells cultured in triplicates in 96-well plates at 2×10^5 /well in complete Opti-MEM medium with or w/o granulocyte-macrophage colony-stimulating factor (GM-CSF) at 20 ng/ml were analyzed after 2 days. **(A,B)** Percentages of living cells. Flow cytometry analysis was performed after staining with Annexin V FITC and incubation with PI. **(A)** Typical Annexin V and PI staining profiles. Numbers represent percentages of cells in the indicated quadrants. Living cells are in the lower left quadrant (Annexin V- PI-). **(B)** Summary of results obtained by analyzing living cell percentages among SCF-siRNA and control-scrambled siRNA treated BMdDCs, gated as in **(A)**. Percentages of living cells from individual samples and average values (bar). **(C)** Numbers of living cells. BMdDC numbers were evaluated by the CyQuant assay. Results of SCF-siRNA and control-scrambled siRNA treated samples were normalized over corresponding untreated BMdDCs. Numbers of living cells from individual samples and average values (bar). In **(A)** representative data of $N = 5$ experiments, in **(B,C)** $N = 5$ experiments ($*P \leq 0.05$).

cytometric profiles are shown in **Figures 8A,B** (gating strategy in Figure S1B in Supplementary Material). In agreement with mouse data, we found that cDC1s contained a significantly higher percentage of c-kit⁺ cells than cDC2s (**Figure 8C**). c-Kit histograms suggested that cDC1s represented a homogeneous subset

expressing c-kit at low levels, rather than a heterogeneous population containing a negative and a positive fraction (**Figure 8A**). Further analysis showed that the CD141⁻ fraction in the BM contained cells expressing much higher c-kit levels than cDC1s (**Figure 8B**).



DISCUSSION

Our data show that c-kit⁺ DCs are found in human BM, and mouse spleen and BM. BM c-kit⁺ DCs had intermediate expression of GFP in the CX3cr1^{8fp/+} reporter mouse, distinguishing them from the previously described perivascular BM-resident DC subset (47). By comparing the two cDC subsets in the BM, we found that both human and mouse BM cDC1s were homogeneous cell populations, expressing low and intermediate levels of c-kit, respectively, whereas cDC2s were heterogeneous and differed between humans and mice. c-Kit was expressed by a fraction of mouse BM cDC2s, while human BM cDC2s had little or no expression of c-kit, thus echoing human blood cDC2s (53). The difference in c-kit expression between BM cDC1s and cDC2s is not surprising, in light of the distinct developmental pathways and composition of these two subsets. Indeed, cDC1s are more homogeneous and their development strongly requires the transcription factor BATF3, while cDC2s mostly depend on IRF4 and comprise various subpopulations (2, 14). In further support of cDC2 heterogeneity, we found that—differently from mouse BM cDC2s—mouse spleen cDC2s were virtually all c-kit⁺.

c-kit⁺ DCs represented a small percentage of DCs differentiated from mouse BM cells *in vitro* with either Flt3-L or GM-CSF. It is known that DCs differentiated from BM cells with GM-CSF are heterogeneous for the expression of typical activation markers, e.g., MHC-II, CD40 (54, 55). We followed a widely used protocol to generate DCs (41), and after purification of CD11c⁺ cells at day 7, we obtained a mixture of c-kit⁻ CD40^{int} MHC-II^{int} and c-kit⁺ CD40^{hi} MHC-II^{hi} cells. However, after replating these

BmDCs in complete Opti-MEM medium with GM-CSF for 2 days, we obtained a quite homogeneous set of c-kit⁺ CD40^{hi} MHC-II^{hi} cells, which expressed a functional c-kit receptor, as demonstrated by Akt phosphorylation after a short incubation with SCF. Upon incubation with the model antigen OVA, these cells were able to present OVA-derived peptides to both OT-1 and OT-2 cells, showing that both MHC-I and MHC-II antigen presentation pathways were functional. Results were similar with or without SCF. We also investigated whether CXCR4 expression by BmDCs could be modulated by GM-CSF and/or SCF and observed that GM-CSF negatively regulated CXCR4 membrane expression, while SCF did not have any effect. This suggests that SCF does not regulate retention of DCs in the BM, while GM-CSF might promote DC mobilization out of the BM, by reducing CXCR4 expression. GM-CSF-mediated inhibition of CXCR4 expression by DCs resembles GM-CSF effect on neutrophils (56).

We documented a negative effect of GM-CSF on both c-kit expression and SCF production by BmDCs. Indeed, c-kit expression strikingly increased if GM-CSF was omitted after replating BmDCs in complete Opti-MEM. We also observed that c-kit expression significantly increased at high cell density with GM-CSF at 20 ng/ml, possibly reflecting reduced availability of GM-CSF due to intercellular competition in the culture. The fact that, even without adding GM-CSF, high-density BmDC cultures resulted in increased c-kit expression suggests that further mechanisms regulate c-kit expression, for example, changes in pH, or competition for nutrients in the medium. Furthermore, we showed that BmDCs produced SCF and that both SCF mRNA and protein augmented when cells were cultured without GM-CSF for 2 days after replating. In

particular, cell-associated SCF increased, but not SCF found in the culture supernatant, suggesting either that membrane-bound SCF was the prevalent isoform or that soluble SCF was consumed in the culture.

The inverse correlation between addition of GM-CSF to the culture medium and expression of c-kit/SCF by BMdDCs prompted us to investigate whether autocrine SCF production could play a role in BMdDC survival. In this regard, we found that SCF silencing by siRNA resulted in reduced BMdDC survival, suggesting that SCF could contribute to DC maintenance. The prosurvival role of SCF in DC survival has not been previously recognized, possibly due to the inhibitory effects of GM-CSF on SCF/c-kit axis. Indeed, it should not be overlooked that GM-CSF is widely employed to culture mouse and human DCs *in vitro*, including human DCs used in clinical settings (57–59). Based on our study, alternative methods to culture differentiated DCs *in vitro* might be developed, possibly exploiting SCF/c-kit circuit (60–62).

We speculate that DCs more prominently rely on SCF *in vivo* in some microenvironments, for example, in conditions of low GM-CSF and high SCF concentration, that might be found in some BM niches. To obtain evidence of SCF/c-kit function in differentiated DCs *in vivo*, it would be necessary to develop new models of genetically manipulated mice, as available mutant mice have major developmental defects. Indeed, genetic deficiencies in either c-kit or SCF are often lethal in mice, or can lead to severe defects of hematopoiesis, melanocyte, and germ cell development (63, 64), making it difficult to examine DCs. In case of hypomorphic c-kit mutations, myeloid lineage defects were not usually reported (65), nevertheless the absolute number of CMPs was significantly decreased in mice bearing the W^{41} hypomorphic mutation (66), suggesting an abnormal development of CMP-derived cells, including DCs. Notably, c-kit is expressed not only by CMPs, but also by common DC precursors in the BM (24, 67, 68). Thus, novel tools have to be developed to specifically investigate the role of SCF/c-kit in differentiated DC survival, for example, DC-specific c-kit conditional ko mice.

Our results on c-kit⁺ BM DCs might be relevant for some hematological diseases in which immune responses occur in the BM, such as graft-versus-host disease (GVHD) and graft-versus-leukemia (69–71). It is now recognized that the BM niche for HSC is one of the major targets of GVHD, in addition to gut, liver, and skin (70–72). In this context, local DCs in the BM can orchestrate T cell activation (73), thus regulating target organ damage. Based on our results, it might be speculated that changes in BM SCF levels occurring in BM transplantation (74, 75) can affect DC survival, possibly influencing several steps of local and systemic immune response. Moreover, a reduced expression of either SCF or c-kit might play a role in BM DC survival in some diseases of unclear pathogenesis, for example high-risk myelodysplastic syndromes (76), and sepsis-induced immunosuppression (77, 78).

Notably, c-kit⁺ DCs have been implicated in the immune response against cancer, but their role is still unclear. On one hand, it was proposed that some indirect anticancer effects of therapy with imatinib mesylate might be due to drug-mediated inhibition

of c-kit and/or other tyrosine kinase receptors expressed by DCs (79). On the other hand, microarray analysis of intratumoral DCs from cancers with different prognosis intriguingly demonstrated that the top gene positively correlated with favorable prognosis is c-kit (80). Thus, further studies are required to determine the role of c-kit⁺ DC, including BM cDC1s, in orchestrating either spontaneous or treatment-induced antitumor immunity.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of Institutional Ethics Committee of Centro Traumatologico Ortopedico Andrea Alesini Hospital (ASL Roma C) with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. Approved protocol: study no. 129.14, prot 76699. This study was carried out in accordance with the recommendations of Institutional Ethics Committee of Policlinico Tor Vergata (Fondazione PTV Policlinico Tor Vergata) with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. Approved protocol: study no. 156.15, prot. 0030053/2015. For mouse experiments, this study was carried out in accordance with the recommendations of institutional guidelines of Istituto Superiore di Sanità of Rome (ISS), DL116/92 and 26/2014.

AUTHOR CONTRIBUTIONS

FD designed experiments, interpreted the results, and wrote the paper with help by SS; SV and AQ performed experiments with WT mouse BM and spleen DCs; SV performed experiments with Cx3cr1-mutant mice and WT cDC subsets; ASeijas and SS performed experiments with mouse BMdDCs; ASeijas performed SCF silencing and SCF Elisa experiments; SS analyzed CXCR4, tested SCF effect on antigen presentation, and performed experiments with human BM DCs; FD and SS analyzed flow cytometry data; DR, ASeijas, and ASoriani performed/analyzed Real-Time PCR experiments; MC, IF, and AN performed/analyzed Western Blot experiments; FS, UT, FO, and EP took care of the patients and provided human BM samples; ASantoni provided important conceptual insights.

ACKNOWLEDGMENTS

We thank the patients involved in this study. We thank M. Foti and S. Bulfone-Paus for their feedback and support at the beginning of this project; the students I. Fraudentali and A. Natalini for participating in flow cytometry experiments; M. R. Castrucci for kindly providing OT-1 mice; V. Barnaba, R. Paolini, and S. Amigorena for discussion; A. Gismondi, L. Pace, S. Piconese, and J. Hiscott for reading the manuscript and providing useful advices.

FUNDING

This work was supported by CTN01_00177_962865 (Medintech) grant from Ministero dell'Università e delle Ricerca (MIUR).

SUPPLEMENTARY MATERIALS

The Supplementary Material for this article can be found online at <http://journal.frontiersin.org/article/10.3389/fimmu.2017.00147/full#supplementary-material>.

FIGURE S1 | Gating strategy for mouse and human dendritic cells (DCs).

Cells were stained with fluorochrome-conjugated monoclonal antibodies and analyzed by flow cytometry. **(A)** Mouse bone marrow (BM) and spleen DCs. Gating strategy based on forward and side scatter is shown. In the dump channel, CD3⁺, NK1.1⁺, and PI⁺ cells were excluded. **(B)** Human BM DCs. Gating strategy based on forward and side scatter is shown. The CD45⁺ cells were gated, while CD14⁺, CD19⁺, and dead cell discriminator (DCD)⁺ cells were excluded in the dump channel.

FIGURE S2 | c-Kit membrane expression by dendritic cells (DCs) from WT and Cx3cr1-genetically modified mice. (A,B)

CD11c⁺ cells were enriched from WT bone marrow (BM) and spleen by immunomagnetic selection. **(C,D)** BM and spleen cells were obtained from Cx3cr1^{gfp/+}, Cx3cr1^{gfp/gfp}, and WT mice. Cells were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry. Typical flow cytometric profiles, showing c-kit⁺ cell percentages among CD11c^{high} MHCII⁺ DCs from BM **(A,C)** and spleen **(B,D)**. In the histograms, solid lines represent c-kit staining profiles, dashed lines isotype control mAb. Numbers represent percentages of cells in the indicated regions. In **(A,B)** representative data from *N* = 5 experiments, in **(C,D)** representative data from *N* = 9 in three experiments (1 mouse/group in each experiment).

FIGURE S3 | Gating strategy for dendritic cells (DCs) generated *in vitro* from mouse bone marrow (BM).

Cells were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry. Gating strategy based on forward/side scatter and dead cell exclusion by PI is shown for DCs generated from BM cells with FMS-like tyrosine kinase 3 ligand (Flt3-L) **(A)** and with granulocyte-macrophage colony-stimulating factor (GM-CSF) **(C,E)**. c-kit expression is shown for DCs generated with Flt3-L **(B)** and with GM-CSF **(D,F)**. Panels **(E,F)** show results obtained with GM-CSF after cell purification with anti-CD11c magnetic microbeads. Histograms show results

obtained with CD11c⁺ cells, gated as shown; solid lines represent c-kit staining profiles, dashed lines indicate isotype control mAb.

FIGURE S4 | c-Kit expression by BM-derived DCs (BMdDCs): comparison of different culture media and analysis of adherent and non-adherent cells. (A,B)

Culture media. BMdDCs were plated in 24-well plates and cultured for 2 days with granulocyte-macrophage colony-stimulating factor (GM-CSF) at 20 ng/ml either in complete RPMI medium, or in complete Opti-MEM medium. Complete RPMI medium contains 10% fetal calf serum (FCS); complete Opti-MEM medium is serum free (see Section "Materials and Methods" for details). Cells were stained with fluorochrome-conjugated monoclonal antibodies (mAbs) and analyzed by flow cytometry, as in **Figure 3**. **(A)** Typical flow cytometric profiles, showing CD40 and MHCII expression by BMdDCs. Numbers represent percentages of cells in the indicated regions. **(B)** Typical histograms showing c-kit expression by MHCII^{int} CD40^{int} and MHCII^{hi} CD40^{hi} BMdDCs, gated as in **(A)**. Solid lines represent c-kit staining profiles, dashed lines indicate isotype control mAb. Numbers indicate c-kit median fluorescence intensity values. **(C,D)** Adherent and non-adherent cells. BMdDCs were plated in 24-well plates and cultured for 2 days in complete Opti-MEM medium with GM-CSF at 20 ng/ml, before harvesting either non-adherent cells or adherent cells after detachment with PBS 10 mM EDTA. Cells were analyzed and results represented as in **(A,B)**. In **(A,B)** representative data from *N* = 3 experiments; in **(C,D)** representative data from *N* = 5 experiments.

FIGURE S5 | Negative effect of anti-c-kit blocking monoclonal antibody (mAb) on BM-derived DC (BMdDC) survival.

BMdDCs were cultured for 2 days in triplicates in 96-well plates at 2 × 10⁵/well in complete Opti-MEM medium in four different conditions, that is either with or without (w/o) granulocyte-macrophage colony-stimulating factor (GM-CSF), and in the presence of 10 μg/ml of either the anti-c-kit blocking mAb ACK2 or its isotype control (ctrl) mAb, as indicated. Flow cytometry analysis was performed after staining with Annexin V FITC and incubation with PI. **(A)** Typical Annexin V and PI staining profiles. Numbers represent percentages of cells in the corresponding quadrants. Living cells are in the lower left quadrant (Annexin V⁻ PI⁻). **(B)** Summary of results. Percentages of living cells from individual samples treated either with anti-c-kit or control mAb. In **(A)** representative data of *N* = 4 experiments, in **(B)** *N* = 4 experiments (**P* < 0.05).

REFERENCES

- Zanoni I, Granucci F. The regulatory role of dendritic cells in the induction and maintenance of T-cell tolerance. *Autoimmunity* (2011) 44:23–32. doi:10.3109/08916931003782148
- Mildner A, Jung S. Development and function of dendritic cell subsets. *Immunity* (2014) 40:642–56. doi:10.1016/j.immuni.2014.04.016
- Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. *Eur J Immunol* (1998) 28:2760–9. doi:10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N
- Sozzani S. Dendritic cell trafficking: more than just chemokines. *Cytokine Growth Factor Rev* (2005) 16:581–92. doi:10.1016/j.cytogfr.2005.04.008
- Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, van der Velden AW, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. *Nat Immunol* (2005) 6:1029–37. doi:10.1038/nri1249
- Ricart BG, John B, Lee D, Hunter CA, Hammer DA. Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4. *J Immunol* (2011) 186:53–61. doi:10.4049/jimmunol.1002358
- Zelenay S, Keller AM, Whitney PG, Schraml BU, Deddouch S, Rogers NC, et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. *J Clin Invest* (2012) 122:1615–27. doi:10.1172/JCI60644
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* (1998) 392:245–52. doi:10.1038/32588
- Merad M, Manz MG. Dendritic cell homeostasis. *Blood* (2009) 113:3418–27. doi:10.1182/blood-2008-12-180646
- Zou J, Kawai T, Tsuchida T, Kozaki T, Tanaka H, Shin KS, et al. Poly IC triggers a cathepsin D- and IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis. *Immunity* (2013) 38:717–28. doi:10.1016/j.immuni.2012.12.007
- Dubois SP, Waldmann TA, Muller JR. Survival adjustment of mature dendritic cells by IL-15. *Proc Natl Acad Sci U S A* (2005) 102:8662–7. doi:10.1073/pnas.0503360102
- Yen JH, Ganea D. Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. *Blood* (2009) 114:1344–54. doi:10.1182/blood-2008-12-196592
- Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. *Annu Rev Immunol* (2013) 31:563–604. doi:10.1146/annurev-immunol-020711-074950
- Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. *Nat Rev Immunol* (2014) 14:571–8. doi:10.1038/nri3712
- Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. *Nat Rev Immunol* (2007) 7:19–30. doi:10.1038/nri1996
- Sozzani S, Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. *Trends Immunol* (2010) 31:270–7. doi:10.1016/j.it.2010.05.004
- Bar-On L, Birnberg T, Lewis KL, Edelson BT, Bruder D, Hildner K, et al. CX3CR1+ CD8alpha+ dendritic cells are a steady-state population related to plasmacytoid dendritic cells. *Proc Natl Acad Sci U S A* (2010) 107:14745–50. doi:10.1073/pnas.1001562107
- Kassianos AJ, Wang X, Sampangi S, Afrin S, Wilkinson R, Healy H. Fractalkine-CX3CR1-dependent recruitment and retention of human

- CD1c+ myeloid dendritic cells by in vitro-activated proximal tubular epithelial cells. *Kidney Int* (2015) 87:1153–63. doi:10.1038/ki.2014.407
19. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. Origin of dendritic cells in peripheral lymphoid organs of mice. *Nat Immunol* (2007) 8:578–83. doi:10.1038/ni1462
 20. Vremec D, Lieschke GJ, Dunn AR, Robb L, Metcalf D, Shortman K. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. *Eur J Immunol* (1997) 27:40–4. doi:10.1002/eji.1830270107
 21. Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. *Blood* (2009) 114:835–43. doi:10.1182/blood-2009-02-206318
 22. van de Laar L, Coffey PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. *Blood* (2012) 119:3383–93. doi:10.1182/blood-2011-11-370130
 23. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. *Nat Immunol* (2008) 9:676–83. doi:10.1038/ni.1615
 24. Haniffa M, Collin M, Ginhoux F. Ontogeny and functional specialization of dendritic cells in human and mouse. *Adv Immunol* (2013) 120:1–49. doi:10.1016/B978-0-12-417028-5.00001-6
 25. Oriss TB, Krishnamoorthy N, Raundhal M, Morse C, Chakraborty K, Khare A, et al. Cutting Edge: MMP-9 inhibits IL-23p19 expression in dendritic cells by targeting membrane stem cell factor affecting lung IL-17 response. *J Immunol* (2014) 192:5471–5. doi:10.4049/jimmunol.1303183
 26. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yarlagadda M, Vanhaesebroeck B, et al. Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. *Nat Med* (2008) 14:565–73. doi:10.1038/nm1766
 27. Yang B, Yang Q, Huang Q, Yan H, Sun T, Tong H. Silencing c-Kit expression in human DCs suppresses Th2, Th17 response but enhances Th1 response. *Am J Transl Res* (2015) 7:1499–509.
 28. Adachi Y, Taketani S, Toki J, Ikebukuro K, Sugiura K, Oyaizu H, et al. Marked increase in number of dendritic cells in autoimmune-prone (NZW x BXSB)F1 mice with age. *Stem Cells* (2002) 20:61–72. doi:10.1634/stemcells.20-1-61
 29. Huang EJ, Nocka KH, Buck J, Besmer P. Differential expression and processing of two cell associated forms of the kit-ligand: KL-1 and KL-2. *Mol Biol Cell* (1992) 3:349–62. doi:10.1091/mbc.3.3.349
 30. Heinrich MC, Dooley DC, Freed AC, Band L, Hoatlin ME, Keeble WW, et al. Constitutive expression of steel factor gene by human stromal cells. *Blood* (1993) 82:771–83.
 31. Broudy VC. Stem cell factor and hematopoiesis. *Blood* (1997) 90:1345–64.
 32. Roskoski RJ. Signaling by Kit protein-tyrosine kinase – the stem cell factor receptor. *Biochem Biophys Res Commun* (2005) 337:1–13. doi:10.1016/j.bbrc.2005.08.055
 33. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. *Eur J Pharmacol* (2006) 533:327–40. doi:10.1016/j.ejphar.2005.12.067
 34. Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. *Physiol Rev* (2012) 92:1619–49. doi:10.1152/physrev.00046.2011
 35. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. *Immunol Cell Biol* (1998) 76:34–40. doi:10.1046/j.1440-1711.1998.00709.x
 36. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. *Cell* (1994) 76:17–27. doi:10.1016/0092-8674(94)90169-4
 37. Ponzetta A, Sciume G, Benigni G, Antonangeli F, Morrone S, Santoni A, et al. CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation. *J Immunol* (2013) 191:5684–94. doi:10.4049/jimmunol.1300090
 38. Quinci AC, Vitale S, Parretta E, Soriani A, Iannitto ML, Cipitelli M, et al. IL-15 inhibits IL-7Ralpha expression by memory-phenotype CD8(+) T cells in the bone marrow. *Eur J Immunol* (2012) 42:1129–39. doi:10.1002/eji.201142019
 39. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. *J Immunol* (2005) 174:7654–64. doi:10.4049/jimmunol.174.12.7654
 40. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med* (1992) 176:1693–702. doi:10.1084/jem.176.6.1693
 41. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods* (1999) 223:77–92. doi:10.1016/S0022-1759(98)00204-X
 42. Sathe P, Pooley J, Vremec D, Mintern J, Jin JO, Wu L, et al. The acquisition of antigen cross-presentation function by newly formed dendritic cells. *J Immunol* (2011) 186:5184–92. doi:10.4049/jimmunol.1002683
 43. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. *Nat Immunol* (2008) 9:558–66. doi:10.1038/ni.1601
 44. Cebrian I, Visentin G, Blanchard N, Jouve M, Bobard A, Moita C, et al. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. *Cell* (2011) 147:1355–68. doi:10.1016/j.cell.2011.11.021
 45. Alloatti A, Kotsias F, Pauwels AM, Carpiere JM, Jouve M, Timmerman E, et al. Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens. *Immunity* (2015) 43:1087–100. doi:10.1016/j.immuni.2015.11.006
 46. Filippi I, Morena E, Aldinucci C, Carraro F, Sozzani S, Naldini A. Short-term hypoxia enhances the migratory capability of dendritic cell through HIF-1alpha and PI3K/Akt pathway. *J Cell Physiol* (2014) 229:2067–76. doi:10.1002/jcp.24666
 47. Sapozhnikov A, Pewzner-Jung Y, Kalchenko V, Krauthgamer R, Shachar I, Jung S. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. *Nat Immunol* (2008) 9:388–95. doi:10.1038/ni1571
 48. Wang Y, Huang G, Vogel P, Neale G, Reizis B, Chi H. Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function. *Proc Natl Acad Sci U S A* (2012) 109:E343–52. doi:10.1073/pnas.1115635109
 49. Welham MJ, Schrader JW. Modulation of c-kit mRNA and protein by hemopoietic growth factors. *Mol Cell Biol* (1991) 11:2901–4. doi:10.1128/MCB.11.5.2901
 50. Welker P, Grabbe J, Zuberbier T, Grutzkau A, Henz BM. GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. *Arch Dermatol Res* (2001) 293:249–58. doi:10.1007/s004030100225
 51. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. *Blood* (2009) 113:4711–9. doi:10.1182/blood-2008-09-177287
 52. Lundberg K, Rydnert E, Greiff L, Lindstedt M. Human blood dendritic cell subsets exhibit discriminative pattern recognition receptor profiles. *Immunology* (2014) 142:279–88. doi:10.1111/imm.12252
 53. Breton G, Lee J, Zhou YJ, Schreiber JJ, Keler T, Puhf S, et al. Circulating precursors of human CD1c+ and CD141+ dendritic cells. *J Exp Med* (2015) 212:401–13. doi:10.1084/jem.20141441
 54. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. *Nat Med* (1999) 5:1249–55. doi:10.1038/15200
 55. Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Schraml BU, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. *Immunity* (2015) 42:1197–211. doi:10.1016/j.immuni.2015.05.018
 56. Nagase H, Miyamasu M, Yamaguchi M, Imanishi M, Tsuno NH, Matsushima K, et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. *J Leukoc Biol* (2002) 71:711–7.
 57. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by

- tumor necrosis factor alpha. *J Exp Med* (1994) 179:1109–18. doi:10.1084/jem.179.4.1109
58. Nair S, Archer GE, Tedder TF. Isolation and generation of human dendritic cells. *Curr Protoc Immunol* (2012) 7:32. doi:10.1002/0471142735.im0732s99
 59. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. *Immunity* (2013) 39:38–48. doi:10.1016/j.immuni.2013.07.004
 60. Bonetti MI, Pieri L, Domenici L, Urbani S, Romano G, Aldinucci A, et al. Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. *Blood* (2011) 117:3983–95. doi:10.1182/blood-2010-08-299735
 61. Balan S, Ollion V, Colletti N, Chelbi R, Montanana-Sanchis F, Liu H, et al. Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. *J Immunol* (2014) 193:1622–35. doi:10.4049/jimmunol.1401243
 62. Lundberg K, Albrekt AS, Nelissen I, Santeogoets S, de Gruijl TD, Gibbs S, et al. Transcriptional profiling of human dendritic cell populations and models – unique profiles of in vitro dendritic cells and implications on functionality and applicability. *PLoS One* (2013) 8:e52875. doi:10.1371/journal.pone.0052875
 63. Russell ES. Hereditary anemias of the mouse: a review for geneticists. *Adv Genet* (1979) 20:357–459.
 64. Ashman LK. The biology of stem cell factor and its receptor C-kit. *Int J Biochem Cell Biol* (1999) 31:1037–51. doi:10.1016/S1357-2725(99)00076-X
 65. Reith AD, Rottapel R, Giddens E, Brady C, Forrester L, Bernstein A. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. *Genes Dev* (1990) 4:390–400. doi:10.1101/gad.4.3.390
 66. Lacombe J, Kros G, Tremblay M, Gerby B, Martin R, Aplan PD, et al. Genetic interaction between Kit and Scl. *Blood* (2013) 122:1150–61. doi:10.1182/blood-2011-01-331819
 67. Liu K, Victoria GD, Schwickert TA, Guermontprez P, Meredith MM, Yao K, et al. In vivo analysis of dendritic cell development and homeostasis. *Science* (2009) 324:392–7. doi:10.1126/science.1170540
 68. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, et al. Deciphering the transcriptional network of the dendritic cell lineage. *Nat Immunol* (2012) 13:888–99. doi:10.1038/ni.2370
 69. Li JM, Southerland LT, Lu Y, Darlak KA, Giver CR, McMillin DW, et al. Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. *J Immunol* (2009) 183:7799–809. doi:10.4049/jimmunol.0900155
 70. Mensen A, Johrens K, Anagnostopoulos I, Demski S, Oey M, Stroux A, et al. Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. *Blood* (2014) 124:963–72. doi:10.1182/blood-2013-11-539031
 71. von Bonin M, Bornhauser M. Concise review: the bone marrow niche as a target of graft versus host disease. *Stem Cells* (2014) 32:1420–8. doi:10.1002/stem.1691
 72. Szyska M, Na IK. Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation. *Front Immunol* (2016) 7:118. doi:10.3389/fimmu.2016.00118
 73. Di Rosa F. T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow. *Immunol Cell Biol* (2009) 87:20–9. doi:10.1038/icb.2008.84
 74. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Benedetti Panici P, et al. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. *Blood* (1994) 84:3532–9.
 75. Politikos I, Kim HT, Nikiforow S, Li L, Brown J, Antin JH, et al. IL-7 and SCF levels inversely correlate with T cell reconstitution and clinical outcomes after cord blood transplantation in adults. *PLoS One* (2015) 10:e0132564. doi:10.1371/journal.pone.0132564
 76. Saft L, Bjorklund E, Berg E, Hellstrom-Lindberg E, Porwit A. Bone marrow dendritic cells are reduced in patients with high-risk myelodysplastic syndromes. *Leuk Res* (2013) 37:266–73. doi:10.1016/j.leukres.2012.10.010
 77. Pastille E, Didovic S, Brauckmann D, Rani M, Agrawal H, Schade FU, et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. *J Immunol* (2011) 186:977–86. doi:10.4049/jimmunol.1001147
 78. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol* (2013) 13:862–74. doi:10.1038/nri3552
 79. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. *J Clin Invest* (2004) 114:379–88. doi:10.1172/JCI21102
 80. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* (2014) 26:638–52. doi:10.1016/j.ccell.2014.09.007

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Barroeta Seijas, Simonetti, Vitale, Runci, Quinci, Soriani, Criscuoli, Filippi, Naldini, Sacchetti, Tarantino, Oliva, Piccirilli, Santoni and Di Rosa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.